Nasdaq · CIK 0001840706
SOPH SOPHiA GENETICS SA
Insider trading from SEC Form 4. Last filing 8 d ago. Close $7.22 on Oct 12, 2026, +86% from the 52-week low and -19% from the high.
In brief
SOPHiA GENETICS SA (SOPH) has 131 SEC Form 4 filings on file from 10 insiders, the latest filed on Oct 7, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 32 open-market sells worth $2.4M, net -$2.4M.
108 open-market trades have been scored at SOPH. The newest: George Cardoza (Chief Financial Officer) sold $13k of stock on Oct 5, 2026, filed Oct 7, 2026, scored 17 (weak), under a 10b5-1 plan. The largest of the 50 shown: Jurgi Camblong (Executive Chairman) sold $507k on Jun 29, 2026, scored 18 (weak), under a 10b5-1 plan. 9 insiders sold within 14 days of each other around Oct 5, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Oct 5, 2026.
Last 90 days
Net insider value
-$2.4M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
32
$2.4M by 10 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
SOPHOct 12, 2026 · close 7.22
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at SOPHiA GENETICS SA, scored: the newest 50 of 108.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | George Cardoza Chief Financial Officer sell | $13k 1,592 shares | -1% | +111% from low-8% from high | |
| 30Weak | Jurgi Camblong Executive Chairman sell | $327k 40,172 shares | -1% | +111% from low-8% from high | |
| 17Weak | Philippe Menu Chief Medical Officer sell | $60k 7,394 shares | -4% | +111% from low-8% from high | |
| 29Weak | Ross Muken Chief Executive Officer sell | $80k 9,838 shares | -1% | +111% from low-8% from high | |
| 30Weak | Kevin Puylaert Chief Sales Officer sell | $1,737 216 shares | -0% | +111% from low-8% from high | |
| 17Weak | Zhenyu Xu Chief Scientific Officer sell | $60k 7,394 shares | -1% | +111% from low-8% from high | |
| 16Weak | Abhimanyu Verma Chief Technology Officer sell | $43k 5,284 shares | -3% | +111% from low-8% from high | |
| 16Weak | Manuela Valente Chief People Officer sell | $34k 4,240 shares | -2% | +111% from low-8% from high | |
| 17Weak | Daan Van Well Chief Legal Officer sell | $50k 6,168 shares | -2% | +111% from low-8% from high | |
| 17Weak | George Cardoza Chief Financial Officer sell | $6,447 774 shares | -0% | +140% from low-8% from high | |
| 20Weak | Ross Muken Chief Executive Officer sell | $3,515 422 shares | -0% | +140% from low-8% from high | |
| 16Weak | Philippe Menu Chief Medical Officer sell | $39k 5,000 shares | -2% | - | |
| 15Weak | Zhenyu Xu Chief Scientific Officer sell | $32k 4,000 shares | -1% | - | |
| 23Weak | Jurgi Camblong Executive Chairman sell | $65k 8,500 shares | -0% | +144% from low-15% from high | |
| 16Weak | Daan Van Well Chief Legal Officer sell | $47k 6,168 shares | -2% | - | |
| 17Weak | Kathy L Hibbs director sell | $51k 6,250 shares | -6% | +168% from low-6% from high | |
| 19Weak | Zhenyu Xu Chief Scientific Officer sell | $89k 10,000 shares | -2% | +186% from low0% from high | |
| 17Weak | Kathy L Hibbs director sell | $54k 6,250 shares | -6% | +177% from low0% from high | |
| 16Weak | Philippe Menu Chief Medical Officer sell | $43k 5,000 shares | -2% | +177% from low0% from high | |
| 19Weak | Abhimanyu Verma Chief Technology Officer sell | $85k 10,000 shares | -5% | +165% from low0% from high | |
| 21Weak | Zhenyu Xu Chief Scientific Officer sell | $163k 20,000 shares | -3% | +165% from low0% from high | |
| 4Weak | Manuela Valente Chief People Officer sell | $79k 10,000 shares | -5% | +165% from low0% from high | |
| 16Weak | Philippe Menu Chief Medical Officer sell | $38k 5,000 shares | -2% | +143% from low-2% from high | |
| 15Weak | Zhenyu Xu Chief Scientific Officer sell | $30k 4,000 shares | -1% | +145% from low-1% from high | |
| 27Weak | Jurgi Camblong Executive Chairman sell | $209k 28,500 shares | -1% | +156% from low0% from high | |
| 16Weak | Abhimanyu Verma Chief Technology Officer sell | $38k 5,000 shares | -3% | +156% from low0% from high | |
| 6Weak | Zhenyu Xu Chief Scientific Officer sell | $145k 20,000 shares | -3% | +109% from low-8% from high | |
| 26Weak | Jurgi Camblong Executive Chairman sell | $138k 20,000 shares | -1% | +127% from low0% from high | |
| 18Weak | Zhenyu Xu Chief Scientific Officer sell | $69k 10,000 shares | -2% | +127% from low0% from high | |
| 16Weak | Abhimanyu Verma Chief Technology Officer sell | $35k 5,000 shares | -3% | +127% from low0% from high | |
| 15Weak | Philippe Menu Chief Medical Officer sell | $28k 5,000 shares | -2% | +88% from low-13% from high | |
| 14Weak | Jurgi Camblong Executive Chairman sell | $286k 44,381 shares | -1% | +110% from low0% from high | |
| 22Weak | Jurgi Camblong Executive Chairman sell | $48k 8,500 shares | -0% | +88% from low-6% from high | |
| 15Weak | Philippe Menu Chief Medical Officer sell | $29k 5,000 shares | -2% | +90% from low-4% from high | |
| 10Weak | Zhenyu Xu Chief Scientific Officer sell | $23k 4,000 shares | -1% | +90% from low-4% from high | |
| 25Weak | Jurgi Camblong Executive Chairman sell | $93k 17,685 shares | -0% | +81% from low-9% from high | |
| 17Weak | George Cardoza Chief Financial Officer sell | $8,419 1,592 shares | -1% | +77% from low-11% from high | |
| 25Weak | Jurgi Camblong Executive Chairman sell | $118k 22,486 shares | -1% | +77% from low-11% from high | |
| 16Weak | Philippe Menu Chief Medical Officer sell | $38k 7,393 shares | -3% | +77% from low-11% from high | |
| 27Weak | Ross Muken Chief Executive Officer sell | $51k 9,838 shares | -1% | +77% from low-11% from high | |
| 30Weak | Kevin Puylaert Chief Sales Officer sell | $1,087 216 shares | -0% | +77% from low-11% from high | |
| 16Weak | Zhenyu Xu Chief Scientific Officer sell | $38k 7,393 shares | -1% | +77% from low-11% from high | |
| 15Weak | Abhimanyu Verma Chief Technology Officer sell | $27k 5,285 shares | -3% | +77% from low-11% from high | |
| 10Weak | Manuela Valente Chief People Officer sell | $21k 4,241 shares | -2% | +77% from low-11% from high | |
| 18Weak | Jurgi Camblong Executive Chairman sell | $507k 83,679 shares | -2% | +100% from low0% from high | |
| 19Weak | Jurgi Camblong Chief Executive Officer sell | $298k 51,442 shares | -1% | +90% from low0% from high | |
| 15Weak | Philippe Menu Chief Medical Officer sell | $28k 5,000 shares | -2% | +90% from low0% from high | |
| 16Weak | Abhimanyu Verma Chief Technology Officer sell | $38k 6,944 shares | -3% | +90% from low0% from high | |
| 17Weak | George Cardoza Chief Financial Officer sell | $4,164 774 shares | -0% | +79% from low-3% from high | |
| 15Weak | Ross Muken President sell | $2,270 422 shares | -0% | +79% from low-3% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 5, 2026 | GEORGE CARDOZA Officer | 1,592 0.00% of outstanding | $13k | Oct 5, 2026 | $15k |
| Oct 5, 2026 | JURGI CAMBLONG Director, Officer | 65,672 0.08% of outstanding | $530k | Oct 5, 2026 | $958k |
| Oct 5, 2026 | PHILIPPE MENU Officer | 22,394 0.03% of outstanding | $181k | Oct 5, 2026 | $215k |
| Oct 5, 2026 | ROSS J MUKEN Director, Officer | 9,838 0.01% of outstanding | $79k | Oct 5, 2026 | $55k |
| Oct 5, 2026 | MANUELA VALENTE Officer | 4,240 0.01% of outstanding | $34k | Oct 5, 2026 | $101k |
| Oct 5, 2026 | DAAN GUIDO MARIA VAN WELL Officer | 6,168 0.01% of outstanding | $50k | Oct 5, 2026 | $47k |
| Oct 5, 2026 | ZHENYU XU Officer | 19,394 0.02% of outstanding | $157k | Oct 5, 2026 | $589k |
| Sep 21, 2026 | GEORGE CARDOZA Officer | 774 0.00% of outstanding | $6,339 | Sep 21, 2026 | $13k |
| Sep 21, 2026 | ROSS J MUKEN Director, Officer | 422 0.00% of outstanding | $3,456 | Sep 21, 2026 | $54k |
| Sep 11, 2026 | DAAN GUIDO MARIA VAN WELL Officer | 6,168 0.01% of outstanding | $47k | Sep 11, 2026 | none |
| Aug 27, 2026 | ZHENYU XU Officer | 14,000 0.02% of outstanding | $119k | Aug 27, 2026 | $489k |
| Aug 25, 2026 | KATHY L HIBBS Director | 18,750 0.02% of outstanding | $158k | Aug 25, 2026 | none |
| Aug 20, 2026 | ZHENYU XU Officer | 6,000 0.01% of outstanding | $50k | Aug 20, 2026 | $405k |
| Aug 19, 2026 | ZHENYU XU Officer | 8,000 0.01% of outstanding | $61k | Aug 19, 2026 | $325k |
| Aug 19, 2026 | MANUELA VALENTE Officer | 10,000 0.01% of outstanding | $76k | Aug 19, 2026 | $21k |
| Aug 7, 2026 | JURGI CAMBLONG Director, Officer | 20,000 0.02% of outstanding | $134k | Aug 7, 2026 | $1.6M |
| Aug 7, 2026 | ZHENYU XU Officer | 22,000 0.03% of outstanding | $147k | Aug 7, 2026 | $192k |
| Aug 4, 2026 | JURGI CAMBLONG Director, Officer | 20,000 0.02% of outstanding | $114k | Aug 4, 2026 | $1.5M |
| Aug 4, 2026 | ZHENYU XU Officer | 10,000 0.01% of outstanding | $57k | Aug 4, 2026 | $102k |
| Jul 21, 2026 | JURGI CAMBLONG Director, Officer | 37,000 0.05% of outstanding | $234k | Jul 21, 2026 | $1.3M |
| Jul 20, 2026 | JURGI CAMBLONG Director, Officer | 24,381 0.03% of outstanding | $143k | Jul 20, 2026 | $1.2M |
| Jul 7, 2026 | JURGI CAMBLONG Director, Officer | 24,290 0.03% of outstanding | $130k | Jul 7, 2026 | $1.5M |
| Jul 6, 2026 | GEORGE CARDOZA Officer | 1,592 0.00% of outstanding | $8,517 | Jul 6, 2026 | $23k |
| Jul 6, 2026 | PHILIPPE MENU Officer | 32,393 0.05% of outstanding | $173k | Jul 6, 2026 | $211k |
| Jul 6, 2026 | ROSS J MUKEN Officer | 9,838 0.01% of outstanding | $53k | Jul 6, 2026 | $97k |
Transactions
The newest 50 of 208 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Ross Muken Chief Executive Officer | SOpen-market sale Ordinary Shares10b5-1 | -9,838 | $8.13 | $80k | 660,391 | 8 d ago |
| Oct 5, 2026 | Philippe Menu Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -7,394 | $8.13 | $60k | 200,993 | 8 d ago |
| Oct 5, 2026 | Abhimanyu Verma Chief Technology Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,284 | $8.12 | $43k | 166,887 | 8 d ago |
| Oct 5, 2026 | Kevin Puylaert Chief Sales Officer | SOpen-market sale Ordinary Shares | -185 | $8.06 | $1,491 | 147,763 | 8 d ago |
| Oct 5, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -7,394 | $8.12 | $60k | 545,493 | 8 d ago |
| Oct 5, 2026 | Manuela Valente Chief People Officer | SOpen-market sale Ordinary Shares10b5-1 | -4,240 | $8.13 | $34k | 206,210 | 8 d ago |
| Oct 5, 2026 | Daan Van Well Chief Legal Officer | SOpen-market sale Ordinary Shares10b5-1 | -6,168 | $8.12 | $50k | 332,716 | 8 d ago |
| Oct 5, 2026 | George Cardoza Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -1,592 | $8.10 | $13k | 306,726 | 8 d ago |
| Oct 5, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -40,172 | $8.13 | $327k | 3,395,650 | 8 d ago |
| Oct 5, 2026 | Kevin Puylaert Chief Sales Officer | SOpen-market sale Ordinary Shares | -31 | $7.92 | $246 | 147,732 | 8 d ago |
| Sep 21, 2026 | George Cardoza Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -774 | $8.33 | $6,447 | 308,318 | 23 d ago |
| Sep 21, 2026 | Ross Muken Chief Executive Officer | SOpen-market sale Ordinary Shares10b5-1 | -422 | $8.33 | $3,515 | 670,229 | 23 d ago |
| Sep 14, 2026 | Philippe Menu Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $7.88 | $39k | 208,387 | 29 d ago |
| Sep 14, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -4,000 | $7.88 | $32k | 552,887 | 29 d ago |
| Sep 10, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -8,500 | $7.66 | $65k | 3,435,822 | 31 d ago |
| Sep 11, 2026 | Daan Van Well Chief Legal Officer | SOpen-market sale Ordinary Shares10b5-1 | -6,168 | $7.63 | $47k | 338,884 | 31 d ago |
| Sep 8, 2026 | Kathy L Hibbs director | SOpen-market sale Ordinary Shares10b5-1 | -6,250 | $8.13 | $51k | 96,992 | 35 d ago |
| Aug 27, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $8.91 | $89k | 556,887 | Aug 31, 2026 |
| Aug 25, 2026 | Kathy L Hibbs director | SOpen-market sale Ordinary Shares10b5-1 | -6,250 | $8.68 | $54k | 103,242 | Aug 26, 2026 |
| Aug 25, 2026 | Philippe Menu Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $8.68 | $43k | 213,387 | Aug 26, 2026 |
| Aug 19, 2026 | Abhimanyu Verma Chief Technology Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $8.20 | $41k | 177,171 | Aug 26, 2026 |
| Aug 24, 2026 | Abhimanyu Verma Chief Technology Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $8.80 | $44k | 172,171 | Aug 26, 2026 |
| Aug 19, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $7.94 | $79k | 576,887 | Aug 21, 2026 |
| Aug 19, 2026 | Manuela Valente Chief People Officer | MOption exercise Ordinary Shares10b5-1 | +10,000 | $3.20 | $32k | 220,450 | Aug 21, 2026 |
| Aug 20, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -4,592 | $8.41 | $39k | 572,295 | Aug 21, 2026 |
| Aug 19, 2026 | Manuela Valente Chief People Officer | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $7.94 | $79k | 210,450 | Aug 21, 2026 |
| Aug 21, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,408 | $8.40 | $45k | 566,887 | Aug 21, 2026 |
| Aug 19, 2026 | Manuela Valente Chief People Officer | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Aug 21, 2026 |
| Aug 13, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -4,000 | $7.52 | $30k | 586,887 | Aug 14, 2026 |
| Aug 12, 2026 | Philippe Menu Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $7.52 | $38k | 218,387 | Aug 14, 2026 |
| Aug 7, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -20,000 | $7.23 | $145k | 3,452,822 | Aug 10, 2026 |
| Aug 7, 2026 | Abhimanyu Verma Chief Technology Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $7.60 | $38k | 182,171 | Aug 10, 2026 |
| Aug 10, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -8,500 | $7.61 | $65k | 3,444,322 | Aug 10, 2026 |
| Aug 5, 2026 | Zhenyu Xu Chief Scientific Officer | MOption exercise Ordinary Shares10b5-1 | +3,000 | $3.28 | $9,840 | 603,887 | Aug 7, 2026 |
| Aug 5, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -3,000 | $7.00 | $21k | 600,887 | Aug 7, 2026 |
| Aug 7, 2026 | Zhenyu Xu Chief Scientific Officer | MOption exercise Ordinary Shares10b5-1 | +7,000 | $3.28 | $23k | 607,887 | Aug 7, 2026 |
| Aug 7, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -7,000 | $7.02 | $49k | 600,887 | Aug 7, 2026 |
| Aug 7, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $7.48 | $75k | 590,887 | Aug 7, 2026 |
| Aug 5, 2026 | Zhenyu Xu Chief Scientific Officer | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -3,000 | $3.28 | $9,840 | 7,000 | Aug 7, 2026 |
| Aug 7, 2026 | Zhenyu Xu Chief Scientific Officer | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -7,000 | $3.28 | $23k | 0 | Aug 7, 2026 |
| Aug 4, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -20,000 | $6.92 | $138k | 3,472,822 | Aug 5, 2026 |
| Aug 4, 2026 | Zhenyu Xu Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $6.92 | $69k | 600,887 | Aug 5, 2026 |
| Aug 4, 2026 | Abhimanyu Verma Chief Technology Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $6.95 | $35k | 187,171 | Aug 5, 2026 |
| Jul 27, 2026 | Philippe Menu Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $5.66 | $28k | 223,387 | Jul 28, 2026 |
| Jul 20, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -19,800 | $6.32 | $125k | 3,512,822 | Jul 22, 2026 |
| Jul 20, 2026 | Jurgi Camblong Executive Chairman | MOption exercise Ordinary Shares10b5-1 | +4,581 | $3.16 | $14k | 3,517,403 | Jul 22, 2026 |
| Jul 20, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -4,581 | $6.17 | $28k | 3,512,822 | Jul 22, 2026 |
| Jul 21, 2026 | Jurgi Camblong Executive Chairman | SOpen-market sale Ordinary Shares10b5-1 | -20,000 | $6.63 | $133k | 3,492,822 | Jul 22, 2026 |
| Jul 20, 2026 | Jurgi Camblong Executive Chairman | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -4,581 | $0.00 | $0 | 0 | Jul 22, 2026 |
| Jul 13, 2026 | Philippe Menu Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $5.70 | $29k | 228,387 | Jul 14, 2026 |
50 of 208 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- George CardozaChief Financial Officer
- Jurgi CamblongExecutive Chairman
- Kathy L Hibbsdirector, officer
- Philippe MenuChief Medical Officer
- Ross MukenChief Executive Officer
- Kevin PuylaertChief Sales Officer
- Manuela ValenteChief People Officer
- Daan Van WellChief Legal Officer
- Abhimanyu VermaChief Technology Officer
- Zhenyu XuChief Scientific Officer
Questions about SOPH
Answered from the filings on this page, as of the latest one.
Are insiders buying SOPH?
As of Oct 7, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 32 open-market sells worth $2.4M by 10 insiders at SOPHiA GENETICS SA in the last 90 days, net -$2.4M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade SOPH on the open market?
George Cardoza (Chief Financial Officer) sold $13k of SOPH on Oct 5, 2026 and filed the Form 4 on Oct 7, 2026. InsiderTell scored 17 (weak), under a 10b5-1 plan, with 9 insiders on the same side within 14 days.
How many insiders file Form 4 at SOPHiA GENETICS SA?
10 people have filed a Form 4 at SOPHiA GENETICS SA, among them George Cardoza (Chief Financial Officer), Jurgi Camblong (Executive Chairman), Kathy L Hibbs (director and officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.